Hepatic arterial infusion chemotherapy using totally implantable port system

Because of low grade of response rate and high grade of toxicity, arterial infusion chemotherapy (AIC) is not the first choice therapy for hepatocellular carcinoma (HCC). Only far advanced HCC patients, who have no indication of surgical, transcatheter arterial embolization nor ablation therapy, are able to accept AIC. The AIC using totally implantable port system has an advantage for patient's quality of life in the long term. We recommend new intensive EEP regimen which has the response rate of 43% although its severe toxicity.